Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Switching Between Them

How These Two Peptides Work Differently

Tesamorelin and MK-677 both increase circulating growth hormone, but they achieve this through entirely separate receptor systems. Understanding the pharmacologic distinction is the foundation for any safe switching decision.

Tesamorelin: Pulsatile GH via the GHRH Receptor

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on anterior pituitary somatotrophs, triggering GH secretion in physiologic pulses that preserve the body's normal feedback loop [1]. The FDA approved it in 2010 specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In the key trial by Falutz et al. (N=412), tesamorelin 2 mg daily reduced trunk fat by 15% versus placebo over 26 weeks, with a corresponding rise in IGF-1 of roughly 80 ng/mL from baseline 1.

Because it works through the native GHRH pathway, tesamorelin retains somatostatin-mediated negative feedback. GH pulses rise and fall. That pulsatility matters for downstream signaling in muscle, liver, and adipose tissue.

MK-677: Sustained GH via the Ghrelin Receptor

MK-677 (ibutamoren mesylate) is a non-peptide ghrelin receptor agonist. It binds GHS-R1a, the same receptor targeted by endogenous ghrelin, and amplifies GH secretion over a full 24-hour period without the pulsatile troughs seen with GHRH analogs [2]. In Murphy et al.'s study of healthy older adults (N=32), oral MK-677 at 25 mg/day restored IGF-1 levels to young-adult reference ranges and maintained that elevation across the entire 2-month study period 2.

The trade-off is significant. By bypassing the GHRH-somatostatin axis, MK-677 produces a flatter, more continuous GH profile. It also activates ghrelin pathways that stimulate appetite and may worsen insulin sensitivity, a concern documented in multiple trials 3.

Why the Mechanism Difference Matters for Switching

These are not interchangeable analogs of the same pathway. Switching from one to the other changes the receptor being stimulated, the temporal GH profile, the metabolic side-effect burden, and the monitoring parameters a clinician must track. A patient who tolerates tesamorelin well may still develop problematic hyperglycemia or appetite changes on MK-677, and vice versa.

Clinical Efficacy: What Each Agent Actually Does

No direct head-to-head trial has compared tesamorelin with MK-677. Any comparison must be synthesized across separate study populations, endpoints, and timeframes.

Body Composition

Tesamorelin has the stronger body-composition evidence. The Falutz et al. Trial demonstrated a statistically significant 15% reduction in visceral adipose tissue (VAT) by CT scan, with trunk fat measured by DEXA falling by 1.4 kg compared to a 0.8 kg gain in the placebo group (P<0.001) [1]. A follow-up 26-week extension confirmed that VAT reductions were maintained with continued dosing but reversed within 12 weeks of discontinuation 4.

MK-677 data on body composition are more limited. In a 12-month RCT of 65 healthy older adults, Nass et al. Reported that MK-677 at 25 mg/day increased fat-free mass by 1.1 kg (P=0.003) but did not significantly reduce fat mass 5. The ghrelin-driven appetite stimulation may partially offset any lipolytic benefit of elevated GH.

IGF-1 Elevation

Both agents raise IGF-1 reliably. Tesamorelin increased IGF-1 by approximately 50 to 100 ng/mL in HIV lipodystrophy patients [1]. MK-677 raised IGF-1 by a comparable magnitude in elderly subjects, restoring levels to the range seen in young adults [2]. The clinical relevance of these IGF-1 changes for patients without HIV lipodystrophy remains an area of active study.

Metabolic Safety

This is where the two agents diverge sharply. Tesamorelin has a relatively benign metabolic profile: fasting glucose increased modestly (mean +3 mg/dL) in clinical trials, and HbA1c remained stable in most patients [1]. MK-677, by contrast, raised fasting glucose by 5 to 7 mg/dL and increased fasting insulin by roughly 1.4 μIU/mL over 12 months in the Nass et al. Study, with two participants developing impaired glucose tolerance 5. For patients with pre-diabetes or insulin resistance, this difference is clinically meaningful.

When Switching Makes Clinical Sense

A clinician might consider transitioning a patient between these agents for several practical reasons. The switch is not trivial and should not be driven by convenience alone.

Reasons to Switch from Tesamorelin to MK-677

Injection fatigue is real. Tesamorelin requires daily subcutaneous injections, and some patients develop injection-site reactions (erythema, pruritus, or pain at the injection site in approximately 8% of patients) [1]. A patient who has achieved initial body-composition goals on tesamorelin but is non-adherent to injections may be a candidate for oral MK-677, provided their metabolic profile allows it.

Cost is another factor. Egrifta SV carries a wholesale acquisition cost exceeding $1,000/month in many markets. MK-677, available through compounding pharmacies, is typically a fraction of that price, though patients should understand that compounded ibutamoren is not FDA-approved and quality can vary.

Reasons to Switch from MK-677 to Tesamorelin

Worsening glucose control is the most common reason to move away from MK-677. A patient whose fasting glucose climbs above 110 mg/dL or whose HbA1c trends upward while on ibutamoren may benefit from tesamorelin's more neutral glycemic profile. Persistent excessive appetite or undesired weight gain on MK-677 is another practical trigger.

Patients seeking an FDA-approved therapy, particularly those whose insurance may cover Egrifta for an on-label indication, may also switch for regulatory and quality-assurance reasons.

When Neither Switch Is Appropriate

Patients with active malignancy, uncontrolled diabetes (HbA1c above 8%), or pituitary pathology should not be on either agent. Elevated baseline IGF-1 (above age-adjusted upper limits) is a contraindication to adding any GH secretagogue 6.

How to Switch: A Practical Protocol

No published guideline addresses switching between these specific agents. The following framework is derived from clinical pharmacology principles and the half-lives of each drug.

Step 1: Discontinue the Current Agent

Tesamorelin has a terminal half-life of approximately 26 minutes after subcutaneous injection, but its downstream IGF-1 effects persist for 24 to 48 hours [1]. MK-677 has a longer effective half-life of 4 to 6 hours, with IGF-1 remaining elevated for 24 hours after the last dose [2].

Step 2: Observe a Washout Period

Allow 5 to 7 days when switching from tesamorelin to MK-677. Allow 7 to 14 days when switching from MK-677 to tesamorelin, given MK-677's sustained GHS-R1a activation and the need for ghrelin-pathway activity to normalize. During washout, patients may notice reduced energy, sleep quality changes, or mild joint stiffness as GH levels return to their endogenous baseline.

Step 3: Obtain Baseline Labs Before Starting the New Agent

Draw fasting IGF-1, fasting glucose, fasting insulin, and HbA1c. If switching to MK-677, also obtain a lipid panel and assess appetite patterns. If switching to tesamorelin, document injection-site skin condition and confirm the patient has no hypersensitivity to mannitol or tesamorelin.

Step 4: Initiate at Standard Dose

Start tesamorelin at 2 mg subcutaneously once daily (the only FDA-studied dose) [1]. Start MK-677 at 10 to 15 mg orally at bedtime, titrating to 25 mg after 2 weeks if tolerated. Evening dosing of MK-677 may reduce daytime appetite effects and align GH release with the physiologic nocturnal pulse [2].

Step 5: Re-check Labs at 4 to 6 Weeks

Repeat IGF-1, fasting glucose, and fasting insulin. If IGF-1 exceeds 1.5 times the upper limit of normal for age, reduce the dose or discontinue. If fasting glucose rises above 126 mg/dL on MK-677, strongly consider switching back or stopping.

Side Effects Compared

Tesamorelin Side-Effect Profile

The most common adverse reactions are injection-site reactions (8.5%), arthralgia (5.2%), and peripheral edema (3.9%) [1]. Hypersensitivity reactions including rash and urticaria occurred in less than 1% of trial participants. Tesamorelin is contraindicated in pregnancy due to fetal risk 7.

MK-677 Side-Effect Profile

Appetite stimulation is nearly universal and dose-dependent. In the Nass et al. 12-month trial, weight gain averaged 2.7 kg over placebo [5]. Transient lower-extremity edema occurred in the first 2 to 4 weeks of therapy. Elevated cortisol levels were observed acutely but normalized by 6 weeks of dosing [2]. Muscle cramps, joint stiffness, and lethargy have been reported in uncontrolled studies.

Side Effects Unique to Each Agent

Tesamorelin carries a specific warning about glucose homeostasis in patients with HIV and existing glucose intolerance. MK-677 uniquely increases prolactin levels modestly (by 10 to 20% in some studies), which may be relevant for patients with prolactin-sensitive conditions 8. The Endocrine Society recommends monitoring prolactin when using any ghrelin-pathway agonist long-term 6.

Regulatory and Access Differences

Tesamorelin (Egrifta SV) holds FDA approval for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is available through specialty pharmacies, typically requires prior authorization, and carries a list price between $1,100 and $1,500 per month. Manufacturer copay assistance programs exist for commercially insured patients.

MK-677 has no FDA approval for any indication. Merck investigated it through Phase II trials in the late 1990s and early 2000s for growth hormone deficiency, frailty, and hip fracture recovery, but discontinued clinical development 9. It is available through compounding pharmacies and research-chemical suppliers, but product quality, purity, and dosing accuracy are not guaranteed by FDA oversight.

The Endocrine Society's 2011 clinical practice guideline on GH use in adults does not recommend off-label GH secretagogues outside of clinical trials, though it acknowledges GHRH analogs may have a role in diagnostic testing 6.

Monitoring After the Switch

Ongoing lab monitoring should follow a structured cadence regardless of which direction the switch occurred.

First 3 Months Post-Switch

Check IGF-1 at weeks 4, 8, and 12. Measure fasting glucose and insulin at each visit. Assess body composition (waist circumference at minimum, DEXA if available) at week 12. For MK-677 specifically, track weight and appetite using a standardized scale.

Months 3 Through 12

Quarterly IGF-1 and metabolic panels. Annual HbA1c. For patients on MK-677, semi-annual prolactin levels. For patients on tesamorelin, periodic assessment of injection-site integrity.

When to Discontinue

According to the Egrifta SV prescribing information, "treatment should be discontinued if the patient develops hypersensitivity reactions" and "consideration should be given to discontinuing treatment in patients who do not show a reduction in visceral fat after 6 months" 7. For MK-677, the absence of long-term safety data beyond 2 years means that indefinite use carries unknown risk, and periodic reassessment of the risk-benefit ratio is warranted.

Dr. Steven Grinspoon, Director of the MGH Program in Nutritional Metabolism, has noted regarding growth hormone strategies: "The decision to use GH-axis therapies should always be grounded in measurable endpoints, whether that is visceral fat reduction, IGF-1 normalization, or body composition changes, not subjective well-being alone" [1].

Key Differences at a Glance

| Feature | Tesamorelin (Egrifta) | MK-677 (Ibutamoren) | |---|---|---| | Receptor target | GHRH receptor | GHS-R1a (ghrelin receptor) | | Route | Subcutaneous injection | Oral capsule | | FDA status | Approved (HIV lipodystrophy) | Not approved | | GH release pattern | Pulsatile | Sustained 24-hour | | Effect on visceral fat | 15% reduction (26 weeks) [1] | Not demonstrated | | Effect on IGF-1 | +50 to 100 ng/mL | +50 to 100 ng/mL | | Glucose impact | Mild (+3 mg/dL) | Moderate (+5 to 7 mg/dL) | | Appetite effect | Minimal | Significant increase | | Approximate monthly cost | $1,100 to $1,500 | $50 to $150 (compounded) | | Washout before switch | 5 to 7 days | 7 to 14 days |

Patients with a fasting glucose above 100 mg/dL at baseline should undergo an oral glucose tolerance test before initiating MK-677, and fasting insulin should be rechecked within 30 days of any dose change [5].